Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HCA stock price vs ILMN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ILMN's multiple
Needs Annual EPS, ILMN P/E.
Implied fair value · at HCA's multiple
Needs Annual EPS, HCA P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HCA Healthcare, Inc. · implied price per share
Reporting currency could not be verified.
ILLUMINA, INC. · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
HCA · not enough data.
ILMN · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
HCA vs LH
WEST PHARMACEUTICAL SERVICES INC
HCA vs WST
BAXTER INTERNATIONAL INC
HCA vs BAX
MCKESSON CORP
HCA vs MCK
Cigna Group
HCA vs CI
UNITEDHEALTH GROUP INC
HCA vs UNH
THERMO FISHER SCIENTIFIC INC.
HCA vs TMO
AGILENT TECHNOLOGIES, INC.
HCA vs A
DANAHER CORP /DE/
HCA vs DHR
BIO-RAD LABORATORIES, INC.
HCA vs BIO
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
HCA vs PACB
Natera, Inc.
HCA vs NTRA
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HCA deserves only a modest premium to its historical band rather than a full ILMN-multiple rerating, then avoid chasing the 164.8% ILMN-implied upside because ILMN’s valuation is an outlier and HCA’s own fundamentals are solid but not superior on margins or quality.
HCA’s current price of $402.59 sits well below ILMN-implied price of $1,066.14, implying 164.8% upside on the provided P/E framework. However, that gap is largely a function of ILMN’s much richer multiples, not evidence that HCA is fundamentally undervalued versus its own history.
Supporting Metrics
